The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

During a House Energy Committee hearing last week, Rep. Thomas Kean (R-NJ) asked Health and Human Services Secretary Robert F ...

KKR & Co.-backed venture capital firm Catalio Capital Management gathered more than $400 million for its latest fund, a ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

HQH offers high yields with a biotech and small/mid-cap tilt, but relies on capital payouts, making it less tax efficient and ...

A group of 53 biotech leaders are expressing their support for mifepristone in a letter to the Food and Drug Administration, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The head of the EU's pharmaceutical lobby has called for the creation of a life sciences-focused stock market in Europe, ...

The NATO Innovation Fund has made its first investment in a biotechnology company, it said on Monday, seeking to enhance ...

"If a company isn't IPO-ready, it better be M&A-ready," says Nanna Luneborg of Forbion Capital Partners. She and co-founder Sander Slootweg sit down with Bloomberg Intelligence analyst Sam Fazeli to ...